Results 121 to 130 of about 19,533 (266)

Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer. [PDF]

Research (Wash D C)
Ye J, Xie Y, Wang J, Wu R, Li D, Yoo KH, Wusiman D, Cho WC, Lyu Z, Feng D.   +9 more
europepmc   +1 more source

Androgen Receptor Antagonist ONC1-0013B [PDF]

, 2020
openaire   +1 more source

The promise of novel androgen receptor antagonists [PDF]

Cell Cycle, 2010
openaire   +2 more sources

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities. [PDF]

Biomedicines
Wu X, Yi W, Liu X.
europepmc   +1 more source

Androgen Receptor Antagonist BAY 1161116 [PDF]

, 2020
openaire   +1 more source

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Among the approved therapies for metastatic hormone‐sensitive prostate cancer (mHSPC), abiraterone and docetaxel are administered concomitantly with corticosteroids. This study evaluated the association between corticosteroid use and risk of adverse events among patients with mHSPC. Methods We conducted an observational cohort study
Umang Swami, Qiujun Shao, Tamuno Alfred, Maelys Touya, Frank Cao, Pinal Kamdar, Jasmina Ivanova, Johanna Celli, David Nimke   +8 more
wiley   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, EarlyView.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

The intricate interplay between circadian rhythm, androgen signaling, hormone therapy, and cellular senescence in prostate cancer. [PDF]

Cancer Metastasis Rev
Heidari Horestani M, Baniahmad A.
europepmc   +1 more source